Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
75.83 ^USD	-0.35%		+3.44%	+5.28%

Jan. 14	Bio-Techne Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM
Jan. 10	Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine	CI

Gemini Bio-Products, Inc. acquired Assets of Bio-Techne Corporation.

November 24, 2024

Gemini Bio-Products, Inc. acquired Assets of Bio-Techne Corporation (NasdaqGS:TECH) on November 25, 2024.

Gemini Bio-Products, Inc. completed the acquisition of Assets of Bio-Techne Corporation (NasdaqGS:TECH) on November 25, 2024.

Latest news about Bio-Techne Corporation

Bio-Techne Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM	Jan. 14
Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine	Jan. 10	CI
Bio-Techne Prevails in Second Reverse Engineering Claim by Miltenyi Biotec; Shares Up	Jan. 07	MT
Bio-Techne, Waters Strike Co-Marketing, Co-Promotion Deal	Dec. 19	MT
Bio-Techne Signs Distribution Deal With MedSanTek to Expand Product Reach in Turkey	Dec. 12	MT
Medsantek Co. Partners with Bio-Techne Corporation to Bring World-Class Products and Diagnostics in Turkey and Azeri Markets	Dec. 12	CI
Bio-Techne Corporation Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 03:15 PM	Dec. 04
Bio-Techne's Select Fetal Bovine Serum Product Rights, Inventory Acquired by Gemini Bioproducts	Nov. 25	MT
Gemini Bio-Products, Inc. acquired Assets of Bio-Techne Corporation.	Nov. 24	CI
Bio-Techne Corporation Presents at Stephens 26th Annual Investment Conference \| NASH2024, Nov-20-2024 11:00 AM	Nov. 20
Bio-Techne Signs Distribution Deal With Leader Life Sciences	Nov. 20	MT
Bio-Techne Corporation Announces New Distribution Agreement with Leader Life Sciences	Nov. 20	CI
Bio-Techne Corporation Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 08:00 AM	Nov. 19
Bio-Techne Corporation and ALZpath, Inc Announce Strategic Partnership to Advance Neurodegenerative Disease Research	Nov. 18	CI
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo	Nov. 14	CI
Bio-Techne Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 09:30 AM	Nov. 12
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer 39Th Annual Meeting	Nov. 06	CI
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	Nov. 05	CI
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data	Nov. 05	CI
Scotiabank Adjusts Bio-Techne's Price Target to $88 From $83	24-10-31	MT
Baird Adjusts Bio-Techne's Price Target to $84 From $82	24-10-31	MT
Stifel Adjusts Bio-Techne's Price Target to $75 From $65	24-10-31	MT
RBC Adjusts Bio-Techne's Price Target to $79 From $77	24-10-31	MT
Bio-Techne Corporation, Q1 2025 Earnings Call, Oct 30, 2024	24-10-30
Earnings Flash (TECH) BIO-TECHNE CORPORATION Posts Q1 Revenue $289.5M	24-10-30	MT

Chart Bio-Techne Corporation

Duration

Period

TECH: Dynamic Chart

Company Profile

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools 71.5%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (28.1%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ; - other (0.4%). Net sales are distributed geographically as follows: the United States (56.7%), the United Kingdom (4.3%), Europe-Middle East-Africa (20.8%), China (8.6%), Asia-Pacific (6.5%) and others (3.1%).

Employees

3,100

Sector

Biotechnology & Medical Research

Calendar

2025-01-21 - Phacilitate Advanced Therapies Week - Breakout Session

More about the company